Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Dosage
91 Antivenene Pit Viper Injection J06AA03000P3001XX B Treatment of patients who exhibit manifestations of systemic envenoming following a bite by Malayan Pit Viper (Calloselasma rhodostoma). Initial dose of 30ml of reconstituted antivenene given by slow intravenous infusion (2ml/min). Subsequent dose can be given every 6 hours according to the clinical symptoms. As product may differ from batches and manufacturer, it is strongly recommended to refer to the product insert on dosing recommendation.
92 Antivenene Serum (Sea snake) 1000 units Injection J06AA03000P3003XX B Treatment of patients who exhibit manifestations of systemic envenoming following a bite by sea snake. 1000 units by IV infusion over 1/2 to 1 hour. In severe cases 3000 -10000 units may be required
93 Apixaban 2.5mg film coated tablet. B01AF02000T3201XX A* Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Restriction: Only for renal patients. 5 mg taken orally twice daily. Dose reduction: 2.5mg taken orally twice daily in NVAF patients with at least two of the following characteristics: age ≥80 years old, body weight≤60kg, or serum creatinine≥1.5mg/dL (133micromole/L).
94 Apixaban 5mg film coated tablet. B01AF02000T3202XX A* Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Restriction: Only for renal patients. 5 mg taken orally twice daily. Dose reduction: 2.5mg taken orally twice daily in NVAF patients with at least two of the following characteristics: age ≥80 years old, body weight≤60kg, or serum creatinine≥1.5mg/dL (133micromole/L).
95 Aprepitant 125 mg Capsule A04AD12000C1002XX A* In combination with other antiemetic agents for prevention of delayed nausea and vomiting associated with initial and repeat course of highly emetogenic chemotherapy 125 mg 1 hour prior to chemotherapy on Day 1. To be given as part of a 3-day regimen that includes a corticosteroid and a 5-HT3 antagonist
96 Aprepitant 80 mg Capsule A04AD12000C1001XX A* In combination with other antiemetic agents for prevention of delayed nausea and vomitting associated with initial and repeat course of highly emetogenic chemotherapy 80 mg once daily in the morning on Days 2 and Day 3. To be given as part of a 3-day regimen that includes a corticosteroid & a 5-HT3 antagonist
97 Aprotinin 10,000 KIU/ml Injection B02AB01000P3001XX A* Only for Open Heart Surgery (extracorporeal circulation) All patients should receive a 1 ml IV test dose at least 10 minutes prior to loading dose. Initially 2 million KIU bolus followed by 2 million KIU in heart-lung machine followed by a slow infusion of 500,000 KIU/hr until end of surgery. CHILD: 20,000 KIU/kg/day
98 Aqueous Cream D02AX00000G1001XX C+ Dry skin As a soap or apply to the skin as an emollient cream
99 Aripiprazole 10mg Tablet N05AX12000T1001XX A* i) Treatment of acute episodes of schizophrenia and for maintenance of clinical improvement during continuation therapy. ii) Treatment of acute manic episodes associated with bipolar I disorder Schizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day. Bipolar mania: Starting dose: 15 or 30 mg/day. Dose adjustment should occur at intervals of not less than 24 hour
100 Aripiprazole 15mg Tablet N05AX12000T1002XX A* i) Treatment of acute episodes of schizophrenia and for maintenance of clinical improvement during continuation therapy. ii) Treatment of acute manic episodes associated with bipolar I disorder Schizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day. Bipolar mania: Starting dose: 15 or 30 mg/day. Dose adjustment should occur at intervals of not less than 24 hour
101 Arsenic Trioxide 1 mg/ml Injection L01XX27550P3001XX A* Relapsed acute promyelocytic leukaemia (APML). To be prescribed by consultant haematologist only Induction : 0.15 mg/kg/day IV until bone marrow remission. Total induction dose ≤ 60 doses. Consolidation : 0.15 mg/kg/day IV for 25 doses in 5 weeks (5 days per week, followed by 2 days interruption; treatment should begin 3-6 weeks after completion of induction therapy).
102 Artemether 20mg + Lumefantrine 120mg Tablet P01BE52981T1001XX B Acute uncomplicated falciparum malaria ADULT and CHILD over 12 years weighing over 35 kg : 4 tablets as a single dose at the time of initial diagnosis, again 4 tablets after 8 hours and then 4 tablets twice daily (morning and evening) on each of the following two days (total course comprises 24 tablets). INFANT and CHILD weighing 5 kg to less than 35 kg : A 6 dose regimen with 1 to 3 tablets per dose, depending on bodyweight
103 Artesunate 100 mg and Mefloquine HCI 220 mg Tablet P01BF02000T1002XX A Treatment of acute uncomplicated Plasmodium falciparummalaria, resulting either from P. falciparum mono-infection or mixed infection with P. vivax. Weight 5-8kg, Age 6-11 months, Dose: One tablet 25/55mg OD x 3 days Weight : 9-17kg, Age 1-6 years, Dose : Two tablet 25/55mg OD x 3 days Weight :18-29kg, Age 7-12 years, Dose :One tablet 100/220mg OD x 3 days Weight ≥30kg, Age ≥13 years, Dose:Two tablet 100/220mg OD x 3 days
104 Artesunate 25 mg and Mefloquine HCI 55 mg Tablet P01BF02000T1001XX A Treatment of acute uncomplicated Plasmodium falciparummalaria, resulting either from P. falciparum mono-infection or mixed infection with P. vivax. Weight 5-8kg, Age 6-11 months, Dose: One tablet 25/55mg OD x 3 days Weight : 9-17kg, Age 1-6 years, Dose : Two tablet 25/55mg OD x 3 days Weight :18-29kg, Age 7-12 years, Dose :One tablet 100/220mg OD x 3 days Weight ≥30kg, Age ≥13 years, Dose:Two tablet 100/220mg OD x 3 days
105 Artesunate 60 mg Injection P01BE03000P3001XX B Treatment of severe malaria in adults and children 2.4mg of artesunate/kg body weight, by intravenous (IV) or intramuscular (IM) injection, at 0, 12 and 24 hours, then once daily until oral treatment can be substituted. For adults and children with severe malaria or who are unable to tolerate oral medicines, artesunate 2.4 mg/kg body weight IV or IM given on admission (time = 0), then at 12 hrs and 24 hrs, then once a day for 5-7 days is the recommended treatment.
106 Artificial tears/eye lubricant ophthalmic gel S01KA02000G32XXXX B Symptomatic relief of severe dry eye conditions and as lens lubricant during ophthalmic diagnostic procedures Instill 1-2 drops in affected eye(s) as needed. Refer to product information leaflet.
107 Artificial tears/eye lubricant ophthalmic ointment S01XA20900G51XXXX A Keeping the eye lubricated and comfortable during the night Apply a small amount into the eye. Refer product information leaflet.
108 Artificial tears/eye lubricant ophthalmic solution S01XA20000D20XXXX B Tear deficiency, ophthalmic lubricant; for relief of dry eyes and eye irritation 1 - 2 drops several times a day. Refer to product information leaflet.
109 Ascorbic Acid 100 mg Tablet A11GA01000T1002XX C+ Vitamin C deficiency ADULT: 100-250 mg once or twice daily CHILD: 100 mg three times daily for one week followed by 100mg daily until symptoms abate.
110 Ascorbic Acid 500 mg Tablet A11GA01000T1003XX C+ Vitamin C deficiency ADULT: 100-250 mg once or twice daily CHILD: 100 mg three times daily for one week followed by 100mg daily until symptoms abate.
111 Ascorbic Acid 500 mg/2 ml Injection A11GA01000P3001XX B For prevention and treatment of scurvy Therapeutic: Not less than 250 mg daily in divided doses
112 Asenapine 10mg Sublingual Tablet N05AH05253T7002XX A* For second or third line treatment in adult for: i) Schizophrenia ii) Bipolar Disorder - Monotherapy: Acute treatment of manic or mixed episodes associated with Bipolar I disorder. - Adjunctive therapy: As adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with Bipolar I Disorder. i) Schizophrenia: - Acute treatment in adults: Recommended starting and target dose of asenapine is 5mg given twice daily. - Maintenance dose: 5mg twice daily. ii) Bipolar Disorder: - Monotherapy: 10mg twice daily. Adjunctive therapy: 5mg twice daily with lithium or valproate. Dose can be increased to 10mg twice daily based on clinical response.
113 Asenapine 5mg Sublingual Tablet N05AH05253T7001XX A* For second or third line treatment in adult for: i) Schizophrenia ii) Bipolar Disorder - Monotherapy: Acute treatment of manic or mixed episodes associated with Bipolar I disorder. - Adjunctive therapy: As adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with Bipolar I Disorder. i) Schizophrenia: - Acute treatment in adults: Recommended starting and target dose of asenapine is 5mg given twice daily. - Maintenance dose: 5mg twice daily. ii) Bipolar Disorder: - Monotherapy: 10mg twice daily. Adjunctive therapy: 5mg twice daily with lithium or valproate. Dose can be increased to 10mg twice daily based on clinical response.
114 Atazanavir 300mg capsule J05AE08-183-C11-01-XXX A* Approved Indication(s): Treatment of HIV-1 infected, antiretroviral treatment experienced adults, in combination with other antiretroviral medicinal products. Prescribing Restriction: For Infectious Disease Consultant use, in patient with treatment failure on NNRTI regime. The recommended dose is 300mg once daily taken with ritonavir 100mg once daily and with food. Ritonavir is used as a booster of atazanavir pharmacokinetics. If atazanavir with ritonavir is co- administrated with didanosine, it is recommended that didanosine be taken 2 hours after atazanavir with ritonavir taken with food.
115 Atenolol 100 mg Tablet C07AB03000T1002XX B Hypertension, angina pectoris, myocardial infarction and arrhythmias Hypertension and arrythmias; 50 - 100 mg daily, Angina; 100 mg daily, Myocardial infarction; individualised
116 Atenolol 50 mg Tablet C07AB03000T1001XX B Hypertension, angina pectoris, myocardial infarction and arrhythmias Hypertension and arrythmias; 50 - 100 mg daily, Angina; 100 mg daily, Myocardial infarction; individualised
117 Atomoxetine HCl 10 mg Capsule N06BA09110C1001XX A* Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10 CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days, then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day
118 Atomoxetine HCl 18 mg Capsule N06BA09110C1002XX A* Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10 CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days, then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day
119 Atomoxetine HCl 25 mg Capsule N06BA09110C1003XX A* Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10 CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days, then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day
120 Atomoxetine HCl 40 mg Capsule N06BA09110C1004XX A* Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10 CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days, then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day

Halaman-halaman